Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

2.0%

5 terminated/withdrawn out of 247 trials

Success Rate

81.5%

-5.0% vs industry average

Late-Stage Pipeline

16%

40 trials in Phase 3/4

Results Transparency

5%

1 of 22 completed trials have results

Key Signals

55 recruiting1 with results5 withdrawn

Enrollment Performance

Analytics

Phase 2
114(55.3%)
Phase 3
36(17.5%)
N/A
34(16.5%)
Phase 1
15(7.3%)
Phase 4
4(1.9%)
Early Phase 1
3(1.5%)
206Total
Phase 2(114)
Phase 3(36)
N/A(34)
Phase 1(15)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (247)

Showing 20 of 247 trials
NCT07303283Phase 2Not Yet Recruiting

Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma

Role: collaborator

NCT07590024Phase 3Recruiting

RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma

Role: collaborator

NCT07618078Recruiting

Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC

Role: collaborator

NCT07613567Phase 3Not Yet Recruiting

A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer

Role: lead

NCT07613905Not ApplicableNot Yet Recruiting

A Prospective Study on the Clinical Value of Skin Test for Oxaliplatin Hypersensitivity Reaction and Its Correlation With Biomarkers

Role: lead

NCT04053205Phase 1Completed

A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Role: collaborator

NCT07584954Phase 1Recruiting

Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors

Role: collaborator

NCT07581834Phase 2Recruiting

Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

Role: lead

NCT04436965Phase 3Recruiting

Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition

Role: collaborator

NCT07311772Phase 3Recruiting

Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid

Role: collaborator

NCT07013461Recruiting

International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer

Role: collaborator

NCT07533825Not ApplicableEnrolling By Invitation

Laparoscopic Staging for Stage III Gastric Cancer

Role: collaborator

NCT06434649Not ApplicableActive Not Recruiting

Posterior Extra-fascial RARP in Intermediate or High Risk Prostate Cancer

Role: collaborator

NCT06417476Phase 2Active Not Recruiting

Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer

Role: collaborator

NCT07256236Phase 2Recruiting

SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer

Role: lead

NCT07492654Phase 4Not Yet Recruiting

Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream

Role: lead

NCT07470840Phase 2Not Yet Recruiting

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

Role: lead

NCT07320963Phase 1Not Yet Recruiting

Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.

Role: collaborator

NCT07469306Phase 2Not Yet Recruiting

Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

Role: lead

NCT07467330Phase 3Recruiting

Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment

Role: lead